1
|
Miyoshi T, Maruyama K, Oku H, Asahara S, Hanada H, Neki R, Yoshimatsu J, Kokame K, Miyata T. Predictive value of protein S-specific activity and ELISA testing in patients with the protein S K196E mutation. Thromb Res 2019; 185:1-4. [PMID: 31731088 DOI: 10.1016/j.thromres.2019.10.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 09/30/2019] [Accepted: 10/28/2019] [Indexed: 11/19/2022]
Affiliation(s)
- Takekazu Miyoshi
- Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Suita, Japan.
| | - Keiko Maruyama
- Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan
| | | | | | - Hironori Hanada
- Biobank, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Reiko Neki
- Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Jun Yoshimatsu
- Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Koichi Kokame
- Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Toshiyuki Miyata
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
| |
Collapse
|
2
|
Miyoshi T, Oku H, Asahara S, Okamoto A, Kokame K, Nakai M, Nishimura K, Otsuka F, Higashiyama A, Yoshimatsu J, Miyata T. Effects of low-dose combined oral contraceptives and protein S K196E mutation on anticoagulation factors: a prospective observational study. Int J Hematol 2019; 109:641-649. [PMID: 30891674 DOI: 10.1007/s12185-019-02633-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2018] [Revised: 03/13/2019] [Accepted: 03/14/2019] [Indexed: 11/25/2022]
Abstract
The association between low-dose combined oral contraceptives (COCs) and anticoagulation factors in Japanese women has been rarely studied. A total of 394 Japanese women with a new beginning cycle of COC use were enrolled, of whom 335 women visited the clinic within 4 weeks after starting the first cycle of COC. Visits occurred in the active phase (272 women) and the placebo phase (63 women). Free protein S (PS) antigen and activity levels and antithrombin activity levels decreased significantly in both the active and placebo phase groups. Protein C (PC) activity levels increased significantly in both groups. Larger reductions in free PS antigen and activity levels occurred with COC comprising either 30 µg ethinylestradiol/desogestrel or 20 µg ethinylestradiol/drospirenone than that comprising 35 µg ethinylestradiol/norethisterone. In four women with the Japanese-specific PS K196E mutation, mean PS activity was 65% before COC use and 57% during COC use, indicating further decrease with COC use. In conclusion, decreased antigen and activity levels of PS and antithrombin and increased activity levels of PC were observed even during the first cycle of low-dose COC use. The effects on PS and PC activities were also observed in the hormone-free interval.
Collapse
Affiliation(s)
- Takekazu Miyoshi
- Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, 5-7- 1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan.
| | | | | | - Akira Okamoto
- Laboratory of Clinical Chemistry, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Koichi Kokame
- Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Michikazu Nakai
- Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Kunihiro Nishimura
- Department of Statistics and Data Analysis, Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Fumiyuki Otsuka
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Aya Higashiyama
- Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan
| | - Jun Yoshimatsu
- Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, 5-7- 1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan
| | - Toshiyuki Miyata
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan
| |
Collapse
|
3
|
Maruyama K, Akiyama M, Miyata T, Kokame K. Protein S K196E mutation reduces its cofactor activity for APC but not for TFPI. Res Pract Thromb Haemost 2018; 2:751-756. [PMID: 30349894 PMCID: PMC6178719 DOI: 10.1002/rth2.12152] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Accepted: 08/13/2018] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Protein S (PS) is an anticoagulant molecule that functions as a cofactor for activated protein C (APC) in the inactivation of activated coagulation factors Va (FVa) and VIIIa. It also serves as a cofactor for tissue factor pathway inhibitor (TFPI) in the efficient inhibition of factor Xa (FXa). The Lys196-to-Glu (K196E, Tokushima) mutation in the EGF-2 domain of PS is a genetic risk factor for venous thromboembolism (VTE) in the Japanese population. OBJECTIVES To investigate the molecular basis of the thrombophilic phenotype of Japanese patients carrying the PS K196E mutation. METHODS We expressed recombinant human PS wild-type (PS-K) and K196E-mutant (PS-E) in CHO cells, and purified them by Ni2+-affinity and anion exchange column chromatography. We investigated the anticoagulant functions of PS-K and PS-E by measuring APC cofactor activity, TFPI cofactor activity, affinity for the β chain of complement component C4b-binding protein (C4BP), and cleavage by thrombin. RESULTS PS-E had approximately 40% APC cofactor activity compared with PS-K in a clotting-based assay and a FVa inactivation assay. The TFPI cofactor activity of PS-E in the FXa inactivation assay was equivalent to that of PS-K in the absence and presence of coagulation factor V. The strengths of PS-E and PS-K binding to the β chain of C4BP were comparable, and both were equally cleaved by thrombin. CONCLUSIONS The PS K196E mutation increases the risk of VTE because of reduced APC cofactor activity but does not alter various other properties, including the TFPI cofactor activity.
Collapse
Affiliation(s)
- Keiko Maruyama
- Department of Molecular PathogenesisNational Cerebral and Cardiovascular CenterSuitaJapan
| | - Masashi Akiyama
- Department of Molecular PathogenesisNational Cerebral and Cardiovascular CenterSuitaJapan
| | - Toshiyuki Miyata
- Department of Cerebrovascular MedicineNational Cerebral and Cardiovascular CenterSuitaJapan
| | - Koichi Kokame
- Department of Molecular PathogenesisNational Cerebral and Cardiovascular CenterSuitaJapan
| |
Collapse
|
4
|
Rivaroxaban Treatment for Warfarin-Refractory Thrombosis in a Patient with Hereditary Protein S Deficiency. Case Rep Hematol 2018; 2018:5217301. [PMID: 29607227 PMCID: PMC5828494 DOI: 10.1155/2018/5217301] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Revised: 12/02/2017] [Accepted: 01/04/2018] [Indexed: 12/16/2022] Open
Abstract
Protein S (PS) deficiency, an autosomal dominant hereditary thrombophilia, is more prevalent in East Asian populations than in Caucasians. PS-deficient patients have historically been administered a heparin product followed by warfarin for the treatment and secondary prevention of venous thromboembolism (VTE). However, warfarin can be ineffective or causes detrimental effects in rare cases. While direct oral anticoagulants (DOACs) are being increasingly used for the treatment and prevention of VTE, their efficacy in PS-deficient patients has not been established. We describe a 91-year-old woman who presented with chronic bilateral lower leg swelling with VTE that was refractory to warfarin anticoagulation therapy for over 1 year. Her recurrent VTE was diagnosed as quantitative hereditary PS deficiency. Rivaroxaban was administered as maintenance therapy instead of warfarin; after 8 weeks, the severities of the patient's leg swelling and venous ulcerations were significantly reduced with rivaroxaban compared to warfarin, thus demonstrating the efficacy of rivaroxaban for warfarin-refractory chronic VTE associated with hereditary PS deficiency. This case illustrates that rivaroxaban can potentially serve as therapeutic agents to treat warfarin-refractory VTE in PS-deficient patients. Further investigations are required to confirm the efficacy of rivaroxaban on the long term in this regard.
Collapse
|
5
|
Xiong S, Zhou Y, Huang X, Yu R, Lai W, Xiong Y. Ultrasensitive direct competitive FLISA using highly luminescent quantum dot beads for tuning affinity of competing antigens to antibodies. Anal Chim Acta 2017; 972:94-101. [DOI: 10.1016/j.aca.2017.03.039] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Revised: 03/14/2017] [Accepted: 03/20/2017] [Indexed: 01/07/2023]
|
6
|
Abstract
Peptide antibodies, with their high specificities and affinities, are invaluable reagents for peptide and protein recognition in biological specimens. Depending on the application and the assay, in which the peptide antibody is to used, several factors influence successful antibody production, including peptide selection and antibody screening. Peptide antibodies have been used in clinical laboratory diagnostics with great success for decades, primarily because they can be produced to multiple targets, recognizing native wildtype proteins, denatured proteins, and newly generated epitopes. Especially mutation-specific peptide antibodies have become important as diagnostic tools in the detection of various cancers. In addition to their use as diagnostic tools in malignant and premalignant conditions, peptide antibodies are applied in all other areas of clinical laboratory diagnostics, including endocrinology, hematology, neurodegenerative diseases, cardiovascular diseases, infectious diseases, and amyloidoses.
Collapse
|
7
|
Miyata T, Maruyama K, Banno F, Neki R. Thrombophilia in East Asian countries: are there any genetic differences in these countries? Thromb J 2016; 14:25. [PMID: 27766051 PMCID: PMC5056495 DOI: 10.1186/s12959-016-0109-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
In recent years, genetic analyses of congenital deficiencies of three anticoagulant proteins, antithrombin, protein C (PC) and protein S (PS), in East Asian patients with venous thromboembolism (VTE) have greatly increased. The PS-K196E mutation is often identified in the Japanese population with an allelic frequency of 0.86 %, and a total of approximately 10,000 Japanese are estimated to be homozygotes. The heterozygotes show PS anticoagulant activities ranging from 40 to 110 %, and 16 % lower mean anticoagulant activity than that in wild-type individuals. Specific assay methods to identify carriers of this mutation have recently been developed. The mutation carriers are at risk of thrombosis during pregnancy but do not appear to be at risk for adverse pregnancy outcomes. To promote future research into this mutation and its relation to thrombosis, a thrombosis-prone mouse strain with the PS K196E mutation has been developed. We found the PS-K196E mutation and the heterozygous PS-deficiency in mice caused increased VTE, but did not cause aggravation of ischemic stroke, unlike factor V Leiden mutation. Importantly, the PS-K196E mutation is only identified in Japanese. This suggests that although East Asian populations including Japanese, Chinese, and Koreans are geographically and genetically close, the PS-K196E mutation seems to be Japanese-specific, suggesting that the mutation is a recent occurrence and fixed within the Japanese population. Some recurrent genetic mutations predisposing to VTE have been reported in Chinese and Korean populations. Although the genetic background for VTE is known to differ between populations with Caucasian descent and East Asian populations, some of the recurrent mutations differ even within the East Asian populations.
Collapse
Affiliation(s)
- Toshiyuki Miyata
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, 5658565 Japan
| | - Keiko Maruyama
- Department of Molecular Pathogenesis, National Cerebral and Cardiovascular Center, Suita, 5658565 Japan
| | - Fumiaki Banno
- Department of Food and Nutrition, Koriyama Women's University, Koriyama, 9638503 Japan
| | - Reiko Neki
- Division of Counseling for Medical Genetics, National Cerebral and Cardiovascular Center, Suita, 5658565 Japan ; Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center, Suita, 5658565 Japan
| |
Collapse
|
8
|
Zhang L, Li D, Li X, Hu L, Cheng M, Xia F, Gong P, Wang B, Ge J, Zhang H, Cai R, Wang Y, Sun C, Feng X, Lei L, Han W, Gu J. LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation. Sci Rep 2016; 6:29344. [PMID: 27385518 PMCID: PMC4935890 DOI: 10.1038/srep29344] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Accepted: 06/17/2016] [Indexed: 01/11/2023] Open
Abstract
The lysin LysGH15, derived from the staphylococcal phage GH15, exhibits a wide lytic spectrum and highly efficient lytic activity against methicillin-resistant Staphylococcus aureus (MRSA). Here, we found that LysGH15 did not induce resistance in MRSA or methicillin-sensitive S. aureus (MSSA) strains after repeated treatment. Although LysGH15 triggered the generation of LysGH15-specific antibodies in mice, these antibodies did not block lytic activity in vitro (nor the binding capacity of LysGH15). More importantly, when the antibody titre was highest in mice immunized with LysGH15, a single intravenous injection of LysGH15 was sufficient to protect mice against lethal infection with MRSA. These results indicated that LysGH15-specific antibodies did not affect the killing efficiency of LysGH15 against MRSA in vitro or in vivo. LysGH15 also reduced pro-inflammatory cytokines in mice with lethal infections. Furthermore, a high-dose LysGH15 injection did not cause significant adverse effects or pathological changes in the main organs of treated animals. These results provide further evidence for the administration of LysGH15 as an alternative strategy for the treatment of infections caused by MRSA.
Collapse
Affiliation(s)
- Lei Zhang
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Dong Li
- Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, P. R. China
| | - Xinwei Li
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Liyuan Hu
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Mengjun Cheng
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Feifei Xia
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Pengjuan Gong
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Bin Wang
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Jinli Ge
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Hao Zhang
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Ruopeng Cai
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Yanmei Wang
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Changjiang Sun
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Xin Feng
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Liancheng Lei
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| | - Wenyu Han
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China.,Jiangsu Co-innovation Center for the Prevention and Control of important Animal Infectious Disease and Zoonoses, Yangzhou 225009, P. R. China
| | - Jingmin Gu
- College of Veterinary Medicine, Jilin University, Changchun 130062, P. R. China
| |
Collapse
|
9
|
Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. Blood 2015; 126:2247-53. [PMID: 26251307 DOI: 10.1182/blood-2015-06-653162] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Accepted: 08/02/2015] [Indexed: 02/06/2023] Open
Abstract
Protein S (PS) acts as an anticoagulant cofactor for activated protein C in regulation of blood coagulation. The K196E mutation in PS is a race-specific genetic risk factor for venous thromboembolism with a prevalence of ∼2% within the Japanese population. To evaluate the thrombosis risk of the PS-K196E mutation, we generated PS-K196E knockin mice and heterozygous PS-deficient mice. We analyzed their thrombotic states, comparing with mice carrying the factor V Leiden mutation (FV-R504Q), a race-specific genetic risk for venous thrombosis in whites. PS-K196E mice grew normally but had decreased activated protein C cofactor activity in plasma. Purified recombinant murine PS-K196E showed the same decreased activated protein C cofactor activity. A deep vein thrombosis model of electrolytic inferior vena cava injury and pulmonary embolism models induced by infusion of tissue factor or polyphosphates revealed that PS-K196E mice, heterozygous PS-deficient mice, and FV-R504Q mice were much more susceptible to venous thrombosis compared with wild-type mice. Transient middle cerebral artery ischemia-reperfusion injury model studies demonstrated that both PS-K196E mice and heterozygous PS-deficient mice had cerebral infarction similar to wild-type mice, consistent with human observations. Our in vitro and in vivo results support a causal relationship between the PS-K196E mutation and venous thrombosis and indicate that PS-K196E mice can provide an in vivo evaluation system to help uncovering racial differences in thrombotic diseases.
Collapse
|